AI Takes Center Stage at AHA 2026. Experts Warn It Must Be Built for Everyone

Artificial intelligence will be one of the dominant themes when the American Heart Association (AHA) convenes its Scientific Sessions 2026 at McCormick Place in Chicago, November 6 to 9. Late-breaking presentations cover AI-read smartwatch ECGs, AI-assisted echocardiography and AI-enabled tele-ECG aimed at underserved populations.

The question hanging over that progress is who benefits. Cardiovascular disease remains the world's leading cause of death, and its heaviest burden falls on low- and middle-income countries. A recent policy brief in Frontiers in Cardiovascular Medicine argues that precision cardiology can become the global standard, "only when designed with equity from inception."

AI moves from demo to late-breaker

A dedicated late-breaking session on AI in cardiovascular diagnosis, Monday, November 9, from 9:45 to 11 a.m., includes several AI-focused late-breaking presentations: consumer smartwatches with AI-enabled ECG for serial home monitoring of left ventricular dysfunction, the AI ECHO INSIGHT trial of AI-assisted echocardiography interpretation, the PROVAR+ external validation of AI-enabled tele-ECG to identify structural heart disease in underserved populations, and LIFE-AI, which pairs AI coronary plaque analysis with CT-derived fractional flow reserve for risk stratification.

The studies arrive as AI becomes routine in cardiology practice. A JAMA study covered by Cardiovascular Business found that more than 950,000 clinicians submitted queries to a single AI clinical platform between January 2024 and June 2026.

For Jose R. Medina-Inojosa, MD, MSc, of the Division of Cardiology at Emory University School of Medicine, the hardest problem is no longer the model itself.

"The single biggest factor is not the accuracy of the algorithm but the pathway from result to action," Medina-Inojosa told MarketScale. "A smartwatch ECG or an AI-read echo only helps if the patient has access to the device, the result lands in a clinical workflow, and someone is resourced and reimbursed to act on it. Too often, the communities with the highest cardiovascular burden are the ones where that last mile is missing."

Designing for equity from the start

Medina-Inojosa is lead author of the policy brief, published July 13 in Frontiers in Cardiovascular Medicine with Fatima Rodriguez of Stanford, Francisco Lopez-Jimenez of Mayo Clinic and Laurence S. Sperling of Emory. It builds on the World Heart Federation's framework, which treats innovation as a public good and health equity as a universal right.

The authors write that many discovery datasets, validation cohorts and reimbursement pathways still reflect high-income settings. That gap risks weaker performance exactly where disease burden is highest. They also stress that precision tools should strengthen evidence-based care and investment in primary care, not replace it.

Asked what equity from inception looks like for a team building an AI-ECG or imaging tool today, Medina-Inojosa pointed to data and design choices made long before launch.

"It means training and validating on data that reflect the people the tool will serve, including community and safety-net settings, lower-cost devices, and imperfect real-world signals, and reporting performance across sex, age, race and ethnicity, and socioeconomic groups before deployment rather than after," he said. "It also means building with frontline clinicians in those settings from the start, and planning for cost, connectivity, and post-deployment monitoring as part of the design, not as an afterthought."

Where it is already working

The brief points to programs in Africa, Latin America and South and Southeast Asia that succeeded because equity was built in early, through local co-development, task-shifting to frontline staff and financing designed for scale. In Nigeria, AI-ECG screening run within maternal care roughly doubled detection of peripartum cardiomyopathy compared with usual obstetric care. In Uganda, non-experts using AI-guided echo were able to identify rheumatic mitral valve disease, with quality review from a central hub.

What to watch in Chicago

For the late-breakers, Medina-Inojosa said the test is whether they prove real-world impact.

"I would watch for whether the late-breakers move beyond discrimination metrics to show that AI changes management, outcomes, or cost, and whether they were tested in the populations where the need is greatest," he said. "Over the next year, I would most like to see pragmatic trials with clinical endpoints and reimbursement models that reward deploying these tools where they can close gaps, not widen them."

Several sessions on the AHA 2026 program speak to how AI can advance equitable innovation.

Session details and context for the "What to watch" table provided by Dr. Medina-Inojosa.

The global calendar keeps the issue in view after AHA. The World Heart Federation has declared 2026 the Year of Neglected Cardiac Diseases, and the 2nd World Congress on Rheumatic Heart Disease runs November 11 to 14 in Perth, Australia. As AI tools mature, the brief's message is that their impact will depend on the strength of the care systems they are built into.

Frequently Asked Questions

When and where is AHA Scientific Sessions 2026?

The American Heart Association's Scientific Sessions 2026 takes place at McCormick Place in Chicago, November 6 to 9.

Which AI studies are being presented at AHA 2026?

A dedicated late-breaking session on AI in cardiovascular diagnosis on Monday, November 9, includes WATCH-LV (smartwatch AI-ECG for left ventricular dysfunction), the AI ECHO INSIGHT trial of AI-assisted echocardiography, the PROVAR+ validation of AI tele-ECG in underserved populations, and LIFE-AI, which pairs AI coronary plaque analysis with CT-derived fractional flow reserve.

What does "equity from inception" mean for cardiology AI?

According to Dr. Jose R. Medina-Inojosa, it means training and validating on data that reflect the people a tool will serve, reporting performance across sex, age, race and ethnicity, and socioeconomic groups before deployment, and building with frontline clinicians while planning for cost, connectivity and post-deployment monitoring.

What is the biggest barrier to AI improving cardiovascular care?

Medina-Inojosa says the single biggest factor is not algorithm accuracy but the pathway from result to action: the patient needs access to the device, the result must land in a clinical workflow, and someone must be resourced and reimbursed to act on it.

Where has equitable AI in cardiology already worked?

In Nigeria, AI-ECG screening within maternal care roughly doubled detection of peripartum cardiomyopathy compared with usual obstetric care. In Uganda, non-experts using AI-guided echo identified rheumatic mitral valve disease, with quality review from a central hub.

Who wrote the policy brief on precision cardiovascular medicine and equity?

Jose R. Medina-Inojosa of Emory is lead author, with Fatima Rodriguez of Stanford, Francisco Lopez-Jimenez of Mayo Clinic and Laurence S. Sperling of Emory. It was published July 13, 2026, in Frontiers in Cardiovascular Medicine.

Sources

• Medina-Inojosa JR, Rodriguez F, Lopez-Jimenez F, Sperling LS. Precision cardiovascular medicine: global imperative for equity through innovation. Front. Cardiovasc. Med. 2026;13:1835607. doi: 10.3389/fcvm.2026.1835607 (CC BY)
• Original interview responses from Jose R. Medina-Inojosa, MD, MSc, Division of Cardiology, Emory University School of Medicine, October 31, 2026
• AHA Scientific Sessions 2026
• TCTMD: What's Going to Be Hot at AHA 2026
• Cardiovascular Business: Clinicians from all specialties use AI to answer cardiology questions
• World Heart Federation: 2026 Year of Neglected Cardiac Diseases
• AHA Scientific Sessions 2026: Late-Breaking Science program
• Cardiovascular Business: AHA announces late-breaking research for Scientific Sessions 2026